Thousands of people from some of Scotland's most deprived communities will get access to Novo Nordisk's GLP-1 agonist Wegovy in a study looking at the real-world impact of weight-loss medicines. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback